Regulation
Longevity Clinic Advertising Review
Summary
Regulatory watch for longevity, regenerative, and clinic advertising claim-risk patterns. The source packet maps this topic to FTC health-product guidance, FDA regenerative medicine consumer-warning context, and FTC enforcement examples involving unsupported stem-cell treatment marketing claims.
Intelligence Take
Use as a cautious claim-risk review, not as a legal conclusion. The record can help reviewers identify substantiation, disease-treatment, and regenerative-medicine marketing risk patterns, but any clinic-specific conclusion would require exact source support.
Evidence Basis
Source packet maps this record to FTC health-product compliance guidance, an FDA consumer alert on regenerative medicine products including stem cells and exosomes, and FTC enforcement press releases involving stem-cell treatment marketing claims. Evidence stage: regulatory guidance, consumer-warning context, and enforcement examples.
Limitations
Not legal advice and not a clinic-specific legal conclusion. Enforcement examples are source-specific and should not be generalized to every longevity clinic or service model. Any named clinic assessment would require exact official action, claim, jurisdiction, and date context.
Source-reviewed. This record summarizes regulator-source context for public claim-risk review. It is not legal advice or a clinic-specific legal conclusion.